# Safety of and Immune Response to Recombinant Live-Attenuated Parainfluenza Type 1 Virus Vaccine

> **NCT00641017** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 87 (actual)

## Conditions studied

- Parainfluenza
- Virus Diseases

## Interventions

- **BIOLOGICAL:** rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00641017
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2013-02-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00641017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00641017, "Safety of and Immune Response to Recombinant Live-Attenuated Parainfluenza Type 1 Virus Vaccine". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00641017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*